SCHEMBL10249110

SCHEMBL10249110

Cc1ccc2c(c1)nc(-c1ccncc1SCCF)n2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
ATM Q13315 1/20 0.37
AGPAT2 O15120 1/20 0.37
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 2/20 0.37
MAPT P10636 3/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
TP53 P04637 2/20 0.36
CASP1 P29466 1/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
ACSS2 Q9NR19 1/20 0.34
RPS6KA5 O75582 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249150 0.88 TLR8 (0.41) SMN1; SMN2POLBATMAGPAT2KDM4E
SCHEMBL10248957 0.87 SMN1; SMN2 (0.43) SMN1; SMN2POLBATMAGPAT2KDM4E
SCHEMBL10284943 0.87 PDE10A (0.40) SMN1; SMN2POLBATMAGPAT2MAPT
SCHEMBL10249152 0.87 SMN1; SMN2 (0.44) SMN1; SMN2POLBATMAGPAT2KDM4E
SCHEMBL10249144 0.86 SMN1; SMN2 (0.38) SMN1; SMN2POLBATMAGPAT2KDM4E
SCHEMBL10252630 0.85 POLB (0.40) SMN1; SMN2POLBATMAGPAT2KDM4E
SCHEMBL10249017 0.85 MAPT (0.40) SMN1; SMN2POLBATMAGPAT2KDM4E
SCHEMBL10249293 0.83 AKT1 (0.36) SMN1; SMN2POLBRAB9APDE10A
SCHEMBL10249343 0.83 TSHR (0.42) SMN1; SMN2POLBATMAGPAT2KDM4E
SCHEMBL10249306 0.83 SMN1; SMN2 (0.40) SMN1; SMN2POLBATMAGPAT2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885ATM 4476/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885ATM 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.